A Randomized, Investigator-Blinded, Controlled, Split-Scalp Study of the Efficacy and Safety of a 1550-nm Fractional Erbium-Glass Laser, Used in Combination with Topical 5% Minoxidil Versus 5% Minoxidil Alone, for the Treatment of Androgenetic Alopecia

This study evaluated the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia (AGA). The study found that combination therapy was superior to monotherapy in promoting hair growth at week 24, as assessed by two dermatologists and participants. No serious adverse events were reported for either treatment. The study supports the hypothesis that combination therapy can improve the clinical outcomes of hair regrowth. Fractional Er:Glass laser may facilitate transdermal delivery of topical minoxidil.